Member of Lyonbiopole
ENYO Pharma is a privately held clinical stage biopharmaceutical R&D company. Our lead compound Vonafexor modulates NR1H4 which is mainly expressed in the gut, the liver and the kidney.
We develop currently Vonafexor in Phase 2 against a rare kidney diseases, Alport Syndrome and are exploring other ones (e.g. ADPKD,…). Another analog, EYP651, is currently in Phase 1 and profiled against larger renal diseases like CKD or DKD.
ENYO Pharma is currently based in Lyon, France and in Melbourne, Australia.
Strategic application domain: Human Medicine
Application market: Metabolic Disorders - Endocrinology, Rare disease, Urology
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Small Molecules
Created on jan. 14th, 2014 - 10 employees
Address
WELLIO -SILEX 2
9 Rue des Cuirassiers 69003 Lyon
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.